Sugi Predict

Sugi Predict / Compounds / SCHEMBL185191

SCHEMBL185191

SCHEMBL185191

N#Cc1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 2/20 0.58
▸ TRPV4 Q9HBA0 1/20 0.54
▸ VNN1 O95497 1/20 0.44
▸ AR P10275 4/20 0.41
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ CYP3A5 P20815 1/20 0.40
▸ P4HB P07237 1/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.39
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ SLC22A12 Q96S37 3/20 0.38
▸ ELANE P08246 1/20 0.38
▸ TMPRSS4 Q9NRS4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29421437 1.00 KIF11 (0.58) KIF11TRPV4VNN1ARCTSS
SCHEMBL14825521 0.84 TRPV4 (0.51) KIF11TRPV4CYP3A4CYP3A5PTGDR2
SCHEMBL31401031 0.84 TRPV4 (0.51) KIF11TRPV4CYP3A4CYP3A5PTGDR2
SCHEMBL30168580 0.83 KIF11 (0.73) KIF11TRPV4ARCYP3A4CYP3A5
SCHEMBL1727083 0.83 KIF11 (0.73) KIF11TRPV4ARCYP3A4CYP3A5
SCHEMBL7569957 0.83 TRPV4 (0.58) KIF11TRPV4ARCYP3A4CYP3A5
SCHEMBL11966004 0.82 TRPV4 (0.45) KIF11TRPV4SLC22A12
SCHEMBL7604551 0.81 TRPV4 (0.56) KIF11TRPV4ARP4HBMRGPRX4
SCHEMBL2140487 0.79 KIF11 (0.41) KIF11TRPV4VNN1ARSLC22A12
SCHEMBL4927725 0.79 KIF11 (0.41) KIF11TRPV4ARSLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 — — US claimed
CN-102884064-A Process for preparing S1P1 receptor modulators and crystalline forms thereof ARENA PHARM INC 2013-01-16 — — CN claimed
EP-2542554-A1 PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF Arena Pharmaceuticals, Inc. (US) 2013-01-09 — — EP claimed
US-20120329848-A1 PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2012-12-27 — — US claimed
WO-2011109471-A1 PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2011-09-09 — — WO claimed
CN-122079945-A Coumarin derivative containing substituted phenyl ether structure, preparation method and application thereof — 2026-05-26 — — CN disclosed
US-20260049054-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2026-02-19 — — US disclosed
US-12391644-B2 Potassium channel inhibitors SANIONA A/S (DK) 2025-08-19 — — US disclosed
EP-3941903-B1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2025-07-16 — — EP disclosed
WO-2025137605-A1 COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR C4 THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-12234229-B2 Sphingosine kinase inhibitor amidoxime prodrugs UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-02-25 — — US disclosed
US-20240368077-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2024-11-07 — — US disclosed
US-20020183519-A1 Antithrombotic carboxylic acid amides BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-12-05 — — US disclosed
WO-2002072558-A1 ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-09-19 — — WO disclosed
EP-1165493-A1 NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2002-01-02 — — EP disclosed
CN-1326457-A 4-aminopyrrolopyrimidines as kinase inhibitors BASF AG (DE) 2001-12-12 — — CN disclosed
WO-2000058271-A1 NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2000-10-05 — — WO disclosed
EP-0696585-B1 NOVEL BISOXADIAZOLIDINE DERIVATIVE YAMANOUCHI PHARMA CO LTD (JP) 1998-12-16 — — EP disclosed
US-5643931-A ANTIDIABETIC AGENTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1997-07-01 — — US disclosed
EP-0696585-A1 NOVEL BISOXADIAZOLIDINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1996-02-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234229-B2 Sphingosine kinase inhibitor amidoxime prodrugs SPHK1, SPHK2, S1PR2 KIF11 3312/4885TRPV4 2831/4885VNN1 1444/4885
US-12391644-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KIF11 935/4885TRPV4 93/4885VNN1 2918/4885
US-20240368077-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KIF11 1345/4885TRPV4 101/4885VNN1 2877/4885
US-20020183519-A1 Antithrombotic carboxylic acid amides SERPINC1, TFPI, F2 KIF11 4596/4885TRPV4 2850/4885VNN1 2567/4885
US-20260049054-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SCN10A, KCNK10, KCNJ2 KIF11 2328/4885TRPV4 116/4885VNN1 2412/4885
US-20120329848-A1 PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF S1PR1, S1PR5, S1PR2 KIF11 1975/4885TRPV4 944/4885VNN1 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.